- Home
- IOVA vs LVLU Comparison
IOVA vs LVLU Comparison
Compare IOVA & LVLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- LVLU
- Stock Information
- Founded
- IOVA 2007
- LVLU 1996
- Country
- IOVA United States
- LVLU United States
- Employees
- IOVA N/A
- LVLU N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- LVLU Catalog/Specialty Distribution
- Sector
- IOVA Health Care
- LVLU Consumer Discretionary
- Exchange
- IOVA Nasdaq
- LVLU Nasdaq
- Market Cap
- IOVA 1.0B
- LVLU N/A
- IPO Year
- IOVA N/A
- LVLU 2021
- Fundamental
- Price
- IOVA $3.61
- LVLU $0.45
- Analyst Decision
- IOVA Strong Buy
- LVLU Hold
- Analyst Count
- IOVA 9
- LVLU 2
- Target Price
- IOVA $18.22
- LVLU $1.00
- AVG Volume (30 Days)
- IOVA 10.0M
- LVLU 156.4K
- Earning Date
- IOVA 05-08-2025
- LVLU 05-14-2025
- Dividend Yield
- IOVA N/A
- LVLU N/A
- EPS Growth
- IOVA N/A
- LVLU N/A
- EPS
- IOVA N/A
- LVLU N/A
- Revenue
- IOVA $164,070,000.00
- LVLU $315,887,000.00
- Revenue This Year
- IOVA $182.20
- LVLU N/A
- Revenue Next Year
- IOVA $62.10
- LVLU $2.76
- P/E Ratio
- IOVA N/A
- LVLU N/A
- Revenue Growth
- IOVA 13698.99
- LVLU N/A
- 52 Week Low
- IOVA $2.70
- LVLU $0.33
- 52 Week High
- IOVA $14.23
- LVLU $1.99
- Technical
- Relative Strength Index (RSI)
- IOVA 54.38
- LVLU 48.09
- Support Level
- IOVA $2.89
- LVLU $0.37
- Resistance Level
- IOVA $3.43
- LVLU $0.47
- Average True Range (ATR)
- IOVA 0.30
- LVLU 0.06
- MACD
- IOVA 0.10
- LVLU 0.01
- Stochastic Oscillator
- IOVA 95.60
- LVLU 66.67
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.